245 related articles for article (PubMed ID: 35769916)
1. Biomarker Assessment of Homologous Recombination Deficiency in Epithelial Ovarian Cancer: Association With Progression-Free Survival After Surgery.
Yi H; Li L; Huang J; Ma Z; Li H; Chen J; Zheng X; Chen J; He H; Song J
Front Mol Biosci; 2022; 9():906922. PubMed ID: 35769916
[TBL] [Abstract][Full Text] [Related]
2. Modification of Homologous Recombination Deficiency Score Threshold and Association with Long-Term Survival in Epithelial Ovarian Cancer.
How JA; Jazaeri AA; Fellman B; Daniels MS; Penn S; Solimeno C; Yuan Y; Schmeler K; Lanchbury JS; Timms K; Lu KH; Yates MS
Cancers (Basel); 2021 Feb; 13(5):. PubMed ID: 33668244
[TBL] [Abstract][Full Text] [Related]
3. ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer.
Miller RE; Leary A; Scott CL; Serra V; Lord CJ; Bowtell D; Chang DK; Garsed DW; Jonkers J; Ledermann JA; Nik-Zainal S; Ray-Coquard I; Shah SP; Matias-Guiu X; Swisher EM; Yates LR
Ann Oncol; 2020 Dec; 31(12):1606-1622. PubMed ID: 33004253
[TBL] [Abstract][Full Text] [Related]
4. Homologous Recombination Deficiency Assays in Epithelial Ovarian Cancer: Current Status and Future Direction.
Chiang YC; Lin PH; Cheng WF
Front Oncol; 2021; 11():675972. PubMed ID: 34722237
[TBL] [Abstract][Full Text] [Related]
5. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
Liu FW; Tewari KS
Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
[TBL] [Abstract][Full Text] [Related]
6. Homologous recombination deficiency in diverse cancer types and its correlation with platinum chemotherapy efficiency in ovarian cancer.
Wen H; Feng Z; Ma Y; Liu R; Ou Q; Guo Q; Shen Y; Wu X; Shao Y; Bao H; Wu X
BMC Cancer; 2022 May; 22(1):550. PubMed ID: 35578198
[TBL] [Abstract][Full Text] [Related]
7. GIInger predicts homologous recombination deficiency and patient response to PARPi treatment from shallow genomic profiles.
Pozzorini C; Andre G; Coletta T; Buisson A; Bieler J; Ferrer L; Kempfer R; Saintigny P; Harlé A; Vacirca D; Barberis M; Gilson P; Roma C; Saitta A; Smith E; Consales Barras F; Ripol L; Fritzsche M; Marques AC; Alkodsi A; Marin R; Normanno N; Grimm C; Müllauer L; Harter P; Pignata S; Gonzalez-Martin A; Denison U; Fujiwara K; Vergote I; Colombo N; Willig A; Pujade-Lauraine E; Just PA; Ray-Coquard I; Xu Z
Cell Rep Med; 2023 Dec; 4(12):101344. PubMed ID: 38118421
[TBL] [Abstract][Full Text] [Related]
8. Homologous Recombination Deficiency Associated With Response to Poly (ADP-ribose) Polymerase Inhibitors in Ovarian Cancer Patients: The First Real-World Evidence From China.
Ni J; Guo W; Zhao Q; Cheng X; Xu X; Zhou R; Gu H; Chen C; Chen X
Front Oncol; 2021; 11():746571. PubMed ID: 35070965
[TBL] [Abstract][Full Text] [Related]
9. The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it?
Ngoi NYL; Tan DSP
ESMO Open; 2021 Jun; 6(3):100144. PubMed ID: 34015643
[TBL] [Abstract][Full Text] [Related]
10. Update on Poly ADP-Ribose Polymerase Inhibitors in Ovarian Cancer With Non-BRCA Mutations.
Xu Q; Li Z
Front Pharmacol; 2021; 12():743073. PubMed ID: 34912215
[TBL] [Abstract][Full Text] [Related]
11. In-house testing for homologous recombination repair deficiency (HRD) testing in ovarian carcinoma: a feasibility study comparing AmoyDx HRD Focus panel with Myriad myChoiceCDx assay.
Fumagalli C; Betella I; Ranghiero A; Guerini-Rocco E; Bonaldo G; Rappa A; Vacirca D; Colombo N; Barberis M
Pathologica; 2022 Aug; 114(4):288-294. PubMed ID: 36136896
[TBL] [Abstract][Full Text] [Related]
12. Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis.
Lee CK; Friedlander ML; Tjokrowidjaja A; Ledermann JA; Coleman RL; Mirza MR; Matulonis UA; Pujade-Lauraine E; Bloomfield R; Goble S; Wang P; Glasspool RM; Scott CL;
Cancer; 2021 Jul; 127(14):2432-2441. PubMed ID: 33740262
[TBL] [Abstract][Full Text] [Related]
13. A high homologous recombination deficiency score is associated with poor survival and a non-inflamed tumor microenvironment in head and neck squamous cell carcinoma patients.
Chen Y; Zheng X; Lin J; Gao X; Xiong J; Liu J; Fei Z; Chen C
Oral Oncol; 2022 May; 128():105860. PubMed ID: 35428026
[TBL] [Abstract][Full Text] [Related]
14. Homologous Recombination Deficiency Score Determined by Genomic Instability in a Romanian Cohort.
Rădoi VE; Țurcan M; Maioru OV; Dan A; Bohîlțea LC; Dumitrescu EA; Gheorghe AS; Stănculeanu DL; Thodi G; Loukas YL; Săbău ID
Diagnostics (Basel); 2023 May; 13(11):. PubMed ID: 37296748
[TBL] [Abstract][Full Text] [Related]
15. Homologous recombination deficiency and ovarian cancer.
Ledermann JA; Drew Y; Kristeleit RS
Eur J Cancer; 2016 Jun; 60():49-58. PubMed ID: 27065456
[TBL] [Abstract][Full Text] [Related]
16. Homologous recombination repair deficiency (HRD) testing in newly diagnosed advanced-stage epithelial ovarian cancer: A Belgian expert opinion.
Vergote I; Denys H; Altintas S; Kerger J; Baurain JF; Bours V; Henry S; Van de Vijver K; Lambrechts D; Gennigens C
Facts Views Vis Obgyn; 2022 Jun; 14(2):111-120. PubMed ID: 35781107
[TBL] [Abstract][Full Text] [Related]
17. Homologous Recombination Deficiency in Ovarian Cancer: from the Biological Rationale to Current Diagnostic Approaches.
Mangogna A; Munari G; Pepe F; Maffii E; Giampaolino P; Ricci G; Fassan M; Malapelle U; Biffi S
J Pers Med; 2023 Feb; 13(2):. PubMed ID: 36836518
[TBL] [Abstract][Full Text] [Related]
18. Ovarian Cancer Therapy: Homologous Recombination Deficiency as a Predictive Biomarker of Response to PARP Inhibitors.
Miller RE; Elyashiv O; El-Shakankery KH; Ledermann JA
Onco Targets Ther; 2022; 15():1105-1117. PubMed ID: 36217436
[TBL] [Abstract][Full Text] [Related]
19. Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study.
Swisher EM; Aghajanian C; O'Malley DM; Fleming GF; Kaufmann SH; Levine DA; Birrer MJ; Moore KN; Spirtos NM; Shahin MS; Reid TJ; Friedlander M; Steffensen KD; Okamoto A; Sehgal V; Ansell PJ; Dinh MH; Bookman MA; Coleman RL
Gynecol Oncol; 2022 Feb; 164(2):245-253. PubMed ID: 34906376
[TBL] [Abstract][Full Text] [Related]
20. Cracking the homologous recombination deficiency code: how to identify responders to PARP inhibitors.
Paulet L; Trecourt A; Leary A; Peron J; Descotes F; Devouassoux-Shisheboran M; Leroy K; You B; Lopez J
Eur J Cancer; 2022 May; 166():87-99. PubMed ID: 35279473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
